Endeavor Private Wealth Inc. Invests $50,000 in Johnson & Johnson (NYSE:JNJ)

Endeavor Private Wealth Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 342 shares of the company’s stock, valued at approximately $50,000.

Other large investors have also recently added to or reduced their stakes in the company. Raleigh Capital Management Inc. grew its position in shares of Johnson & Johnson by 48.3% during the fourth quarter. Raleigh Capital Management Inc. now owns 14,773 shares of the company’s stock worth $2,136,000 after acquiring an additional 4,810 shares during the last quarter. Asset Planning Services Inc. LA ADV boosted its stake in Johnson & Johnson by 3.1% during the 4th quarter. Asset Planning Services Inc. LA ADV now owns 37,224 shares of the company’s stock valued at $5,383,000 after purchasing an additional 1,120 shares during the period. True North Advisors LLC grew its position in Johnson & Johnson by 2.9% in the 4th quarter. True North Advisors LLC now owns 9,046 shares of the company’s stock worth $1,308,000 after purchasing an additional 253 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Johnson & Johnson by 10.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 1,292,787 shares of the company’s stock valued at $186,963,000 after buying an additional 120,815 shares during the last quarter. Finally, Sharp Financial Services LLC boosted its position in shares of Johnson & Johnson by 14.9% during the fourth quarter. Sharp Financial Services LLC now owns 3,257 shares of the company’s stock worth $471,000 after buying an additional 422 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.1 %

JNJ stock opened at $146.76 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company’s 50 day simple moving average is $147.85 and its 200-day simple moving average is $155.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on JNJ shares. Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Barclays lowered their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 21st. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.